Anti-aging Properties of Melatonin in an in Vitro Murine Senescence Model: Involvement of the Sirtuin 1 Pathway
Overview
Affiliations
Sirtuin 1 is a member of the sirtuin family of protein deacetylases, which have attracted considerable attention as mediators of lifespan extension in several model organisms. Induction of sirtuin 1 expression also attenuates neuronal degeneration and death in animal models of Alzheimer's disease and Huntington's disease. In this study, an in vitro model of neuronal aging was used to test in several ways whether melatonin acts as a sirtuin 1 inducer and if this effect could be neuroprotective. It is shown that melatonin is able to increase the level of this deacetylase in young primary neurons, as well as in aged neurons. We also observed an increase in the deacetylation of several substrates of sirtuin 1, such as p53, PGC-1alpha, FoxO1, ADAM10 and NFkappaB. In addition, there was a reduction in its nuclear translocation and, subsequently, an improvement in transcriptional activity. Sirtinol, a sirtuin 1 inhibitor, was used to correlate these effects with sirtuin. It is shown that sirtinol reduces sirtuin 1 expression and impairs the beneficial action of melatonin on cell viability and apoptosis prevention. Moreover, some of the sirtuin 1 substrates studied also reversed the melatonin effect when sirtinol is added to the cells, mainly p53. Globally, these results add weight to the findings of previous reports, indicating a new role for melatonin in improving cell function gated to an increased neuroprotective role for the sirtuin 1 pathway.
Zimmermann P, Kurth S, Pugin B, Bokulich N NPJ Biofilms Microbiomes. 2024; 10(1):139.
PMID: 39604427 PMC: 11603051. DOI: 10.1038/s41522-024-00605-6.
Modulation of autophagy by melatonin and its receptors: implications in brain disorders.
Zhu C, Li G, Lyu H, Lu Y, Li Y, Zhang X Acta Pharmacol Sin. 2024; 46(3):525-538.
PMID: 39448859 PMC: 11845611. DOI: 10.1038/s41401-024-01398-2.
Melatonin attenuates scopolamine-induced cognitive dysfunction through SIRT1/IRE1α/XBP1 pathway.
Liu X, Huang S, Zheng J, Wan C, Hu T, Cai Y CNS Neurosci Ther. 2024; 30(7):e14891.
PMID: 39056330 PMC: 11273216. DOI: 10.1111/cns.14891.
Mitochondrial targeted antioxidants as potential therapy for huntington's disease.
Upadhayay S, Kumar P Pharmacol Rep. 2024; 76(4):693-713.
PMID: 38982016 DOI: 10.1007/s43440-024-00619-z.
Liu Y, Yao S, Meng Q, Liu X, Han H, Kan C PeerJ. 2023; 11:e15932.
PMID: 37692118 PMC: 10484205. DOI: 10.7717/peerj.15932.